Table 1 Baseline demographics and disease characteristics of the 437 patients with advanced non-small cell lung cancer who were enrolled in the ALTER0303 trial
Characteristic | Placebo arm [cases (%)] | Anlotinib arm [cases (%)] |
|---|---|---|
Total | 143 | 294 |
Gender | ||
Male | 97 (67.8) | 188 (63.9) |
Female | 46 (32.2) | 106 (36.1) |
Smoking status | ||
Never smoked | 66 (46.2) | 151 (51.4) |
Light ex-smoker | 67 (46.9) | 130 (44.2) |
Current smoker | 10 (7.0) | 13 (4.4) |
Baseline ECOG PS | ||
0 | 22 (15.4) | 59 (20.1) |
1 | 120 (83.9) | 233 (79.3) |
2 | 1 (0.7) | 2 (0.7) |
Pathologic type | ||
Adenocarcinoma | 108 (75.5) | 228 (77.6) |
Squamous or adenosquamous cell carcinoma | 33 (23.1) | 53 (18.0) |
Other types | 2 (1.4) | 13 (4.4) |
Clinical stage at screening | ||
IIIB | 7 (4.9) | 15 (5.1) |
IV | 136 (95.1) | 277 (94.2) |
Others | 0 | 2 (0.7) |
Number of metastatic site | ||
≤ 3 | 81 (56.6) | 171 (58.2) |
> 3 | 62 (43.4) | 123 (41.8) |
Surgery history | 91 (63.6) | 153 (52.0) |
Pre-chemotherapy | ||
Two lines | 78 (54.5) | 167 (56.8) |
Three lines or more | 65 (45.5) | 123 (41.8) |
After first line | 0 | 4 (1.4) |
EGFR mutation statusa | ||
Wild-type | 98 (68.5) | 201 (68.4) |
Sensitive mutation | 45 (31.5) | 93 (31.6) |
ALK status | ||
Positive | 2 (1.4) | 5 (1.7) |
Negative | 136 (95.1) | 277 (94.2) |
Unknown | 5 (3.5) | 12 (4.1) |
Pre-TKI usea in EGFR mutation patient | 42 (93%) | 91 (98%) |